Association of leukocyte CR1 gene transcription with the disease severity and renal involvement in systemic lupus erythematosus

Lupus

Volumn 14, Issue 4, 2005, Pages 273-279

  Verma, Jyotsna ^a   Arora, Vaishali ^a   Marwaha, Vishal ^a   Kumar, Ashok ^a   Das, Nibhriti ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Leukocyte CR1; Lupus nephritis; RT PCR; Systemic lupus erythematosus

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR; DNA ANTIBODY; DOUBLE STRANDED DNA; DOUBLE STRANDED DNA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE MEMBRANE; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; LEUKOCYTE; NEPHRITIS; PATHOPHYSIOLOGY; PODOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIGEN-ANTIBODY COMPLEX; CASE-CONTROL STUDIES; COMPLEMENT C3; FEMALE; HUMANS; LEUKOCYTES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; RECEPTORS, COMPLEMENT; TRANSCRIPTION, GENETIC;

EID: 17644420060     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2074oa     Document Type: Article

References (34)

1. Belmont HM. Lupus Clinical Overview 2003 at http://www.cerebel.com/lupus/ overview (accessed 5 November 2004).
2. Hawke CG, Painter DM, Kirwan PD, Van Driel RR, Baxter AG. Mycobacteria, an environmental enhancer of lupus nephritis in a mouse model of systemic lupus erythematosus. Immunology, 2003; 108: 70-78.
3. Dr Koop. Lupus nephritis. Web site: http://www.dr.koop.com (accessed 5 November 2004).
4. Churg J, Bernstein J, Glassock RJ. Renal disease: classification and atlas of glomerular diseases. New York: Igaku-Shoin Medical Publishers, Inc., 1995.
5. Petri M. Treatment of systemic lupus erythematosus: an update. American family physician, published by American Academy of Family Physician. June 1998, 1-11. Web site: www.aafp.org/ofp/980600ap/petri.html (accessed 5 November 2004).
6. Arora M, Arora R, Tiwari SC, Das N Srivastava LM. Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis. Lupus 2000; 9: 127-131.
7. Katyal M, Sivasankar B, Das N. Complement receptor 1 in autoimmune disorders. Current Science 2001; 81: 907-914.
8. Arora V, Verma J, Dutta R, Marwaha V, Kumar A, Das N. Reduced transcription of CR1 (CD35) gene in systemic lupus erythematosus. Mol Immunol 2004; 41: 449-456.
9. Kazatohkine MD, Fearon DT, Appay MD, Mandet C, Bariety J. Immunohistochemical study of human glomerular C3b receptor in normal kidney and in 75 cases of renal diseases: loss of C3b receptor antigen in focal hyalinosis and in proliferative nephritis of SLE. J Clin Invest 1982; 69: 900.
10. Pascual M, Duchosal MA, Steiger G, Giostra E, Pechere A, Schifferli JA. Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes. J Immunol 1993; 151: 1702-1711.
11. Sivashankar B, Dinda AK, Tiwari SC, Srivastava LM, Das N. Modulation of urinary CR1 in systemic lupus erythematosus. Lupus 2004; 13: 1-6.
12. Wilson JG, Ratnoff WD, Schur PH, Fearon DT. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B-lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum 1986; 29: 739-747.
13. Arora M, Jain D, Dinda AK et al. Reduced CR1 expression on erythrocytes of idiopathic focal-segmental glomerulosclerosis patients. Nephron 1998; 79: 365-366.
14. Ross GD, Yount WJ, Walport MJ et al. Disease associated loss of erythrocyte complement receptors (CR1, c3b receptors) in patients with systemic lupus erythematosus and other disease involving autoantibodies and/or complement activation. J Immunol 1985; 135: 2005-2014.
15. Iida K, Nussenzweig V. Complement receptor is an inhibitor of complement cascade. J Exp Med 1982; 153: 1138.
16. Moll S, Mio S, Sadallah S, Gudat F, Mihatsch MJ, Schifferli JA. No complement receptor 1 stump on podocytes in human glomerulopathies, Kidney Internatl 2001; 59: 160-168.
17. Barbosa JE, Harrisson RA, Barker PJ. An anti-peptide Ab that recognizes a neo antigen in CR1 stump remaining on erythrocytes after proteolysis. Clin Exp Immunol 1992; 87: 144-149.
18. Wilson JG, Wong WM, Murphy EE, Schur PH, Fearon DT. Deficiency of the C3b/C4b receptor (CR1) of erythrocytes in systemic lupus erythematosus: analysis of the stability of the defect and of a restriction fragment length polymorphism of the CR1 gene. J Immunol 1987; 138: 2706-2708.
19. Mitchell JA, Sim E. Size polymorphism of the erythrocyte complement receptor type 1 (CR1) in systemic lupus erythematosus induced by hydralazine. Complement and Inflammation 1989; 6: 88-93.
20. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
21. Sai Baba KSS, Moudgil KD, Jain RC, Srivastava LM. Complement activation in pulmonary tuberculosis. Tubercle 1990; 71: 103-107.
22. Wilson JG, Wong WW, Schur PH et al. Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Eng J Med 1982; 307: 981-986.
23. Walport MJ, Ross GD, Mackworth-Young C et al. Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol 1985; 59: 547-554.
24. Iida K, Mornaghi R, Nussenweiz V. Complement receptor 1 deficiency in erythrocytes from patient with systemic lupus erythromatosus. J Exp Med 1981; 155: 1427-1438.
25. Walport MJ, Lachmann PJ. Erythrocytes complement receptor 1, immune complexes and the rhematic diseases. Arthritis Rheum 1988; 31: 153-158.
26. Baral N, Lamsal M, Srivastava LM. Significance of complement profile and complement receptor 1 expression in RBC and kidney tissue in immune complex mediated disease. J Nepal Medical Association 2002; 41: 481-484.
27. Chen CY, Tseng HM, Chen LC et al. Use of new flourescence immunoassay to detect anti-dsDNA antibodies is more correlated with disease activity and complement than the ELISA method in SLE patients. Lupus 2003; 12: 266-273.
28. Alba P, Bento L, Cuadrado MJ et al. Anti-dsDNA, anti-Sm antibodies and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003; 62: 556-560.
29. Reichlin M, Wolfson-Reichlein M. Correlation of anti dsDNA and anti-ribosomal P autoantibodies with lupus nephritis. Clin Immunol 2003; 108: 69-72.
30. Oelzner P, Deliyska B, Funfustuck R, Hein G, Herrmann D, Stein G. Anti-Clq antibodies and antiendothelial cell antibodies in systemic lupus erythematosus-relationship with disease activity and renal involvement. Clin Rheumatol 2003; 22: 271-278.
31. Levinsky RJ, Cameron JS, Soothill JF. Serum immune complexes and disease activity in lupus nephritis. The Lancet 1977; 564-567.
32. Maquart HV, Svendsen A, Ramusen JM, Leslie RGQ. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995; 101: 60-65.
33. Forger F, Mathhias T, Oppermann M, Becker H, Helmke K. Clinical significance of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 2004; 13: 36-44.
34. Navratil JS, Manzi SM, Ruffling MJ et al. A novel complement based for SLE diagnosis and assessment of disease activity. Int Immunopharmacol 2002; 2: 1323 (abstract 310).